Cell and gene therapy firm raises $170M investment

ElevateBio, the local cell and gene therapy holding company created by former executives from Alexion Pharmaceuticals and bluebird bio, is set to move six drugs to clinical trials after raising new financing. ElevateBio aims to create and invest in companies that are developing treatments that directly affect a person’s cells and genes. It was launched last year by former bluebird bio (Nasdaq: BLUE) chief scientific officer Mitchell Finer, and former Alexion Pharmaceuticals (Nasdaq: ALXN) CEO…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news